Last $53.71 USD
Change Today -0.69 / -1.27%
Volume 2.2M
GSK On Other Exchanges
Symbol
Exchange
OTC US
New York
Xetra
London
Mexico
Frankfurt
As of 8:04 PM 07/11/14 All times are local (Market data is delayed by at least 15 minutes).

Transactions by GLAXOSMITHKLINE PLC-SPON ADR (GSK) in the last 6 months

Announced 05/7/14
GlaxoSmithKline plc
Buyback

GlaxoSmithKline plc (LSE:GSK) announces a share repurchase program. Under the program, the company will repurchase up to 486,100,716 shares, representing 10% of its outstanding share capital. The minimum price which may be paid for each ordinary share is 25p. The maximum price which may be paid for each ordinary share shall be the higher of either an amount equal to 5% above the average market value of the company’s ordinary shares for the five business days immediately ...
Read More


GSK's price was unchanged after the transaction was announced on 05/7/14.
 
Announced 04/22/14
16.00B for GlaxoSmithKline plc, Marketed Oncology Portfolio, Related R&D Activities and AKT Inhibitor
Merger/Acquisition

Novartis AG (SWX:NOVN) entered into an agreement to acquire marketed oncology portfolio, related R&D activities and AKT inhibitor from GlaxoSmithKline plc (LSE:GSK) for $16 billion in cash on April 22, 2014. The consideration amount is subject to customary adjustment for levels of working capital. Up to $1.5 billion of the amount depends on the results of the COMBI-d trial. In the event of termination of transaction, GlaxoSmithKline has agreed to pay Novartis a termination ...
Read More


GSK's price was unchanged after the transaction was announced on 04/22/14.
Investor / Buyer
Novartis AG
Creditor / Lender
GlaxoSmithKline plc
 
Announced 04/22/14
7.05B for Novartis AG, Global Vaccines Business
Merger/Acquisition

GlaxoSmithKline plc (LSE:GSK) entered into a share and business sale agreement to acquire global Vaccines business from Novartis AG (SWX:NOVN) for $7.1 billion on April 22, 2014. Under the terms of the agreement, Glaxo agreed to pay $5.25 billion at closing with subsequent potential milestone payments and ongoing royalties, including $450 million upon FDA regulatory approval for Novartis' MenABCWY vaccine product, $450 million in the event that Bexsero achieves an agreed ...
Read More


GSK's price was unchanged after the transaction was announced on 04/22/14.
Investor / Buyer
GlaxoSmithKline plc
Creditor / Lender
Novartis AG
 
Announced 03/28/14
133.00B for GlaxoSmithKline plc, Insto Eye Drops Brand And Manufacturing Site at Bogor
Merger/Acquisition

GlaxoSmithKline plc (LSE:GSK) agreed to sell Insto eye drops brand and manufacturing site at Bogor for approximately IDR 130 billion on March 28, 2014. GlaxoSmithKline will receive combined IDR 133 billion for its Insto eye drops brand and manufacturing site at Bogor. In a related transaction, GSK Consumer Healthcare Pte. Ltd paid IDR 465 billion to Sarasvati Venture Capital Ltd. for the 30% of the Indonesian Consumer Healthcare business it did not previously own. As ...
Read More


GSK's price was unchanged after the transaction was announced on 03/28/14.
Creditor / Lender
GlaxoSmithKline plc
 
Announced 03/28/14
465.00B for Consumer Healthcare Business in Indonesia
Merger/Acquisition

GlaxoSmithKline plc (LSE:GSK) acquired remaining 30% stake in consumer healthcare business in Indonesia for approximately IDR 470 billion on March 28, 2014. In a related transaction, GSK divested its Insto™ eye drops brand to Pharma Healthcare Pte. Ltd and agreed to divest its manufacturing site at Bogor, Indonesia, to PT Pharma Healthcare for a combined total of approximately IDR 130 billion. For the year ending December 31, 2013, consumer healthcare business reported ...
Read More


GSK's price was unchanged after the transaction was announced on 03/28/14.
Investor / Buyer
GlaxoSmithKline plc
 
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GSK:US $53.71 USD -0.69

GSK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
3M Co $144.31 USD +0.42
Bayer AG €101.21 EUR 0.00
Gilead Sciences Inc $88.73 USD -0.21
Novo Nordisk A/S kr247.80 DKK 0.00
PepsiCo Inc $89.85 USD -0.25
View Industry Companies
 

Industry Analysis

GSK

Industry Average

Valuation GSK Industry Range
Price/Earnings 15.4x
Price/Sales 3.0x
Price/Book 11.7x
Price/Cash Flow 15.1x
TEV/Sales 3.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GLAXOSMITHKLINE PLC-SPON ADR, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.